VALNValneva SE

Nasdaq valneva.com


$ 8.61 $ 0.38 (4.9 %)    

Monday, 08-Apr-2024 15:59:35 EDT
QQQ $ 422.80 $ -2.43 (-0.57 %)
DIA $ 377.76 $ 0.39 (0.1 %)
SPY $ 499.54 $ -1.03 (-0.21 %)
TLT $ 88.82 $ -0.45 (-0.5 %)
GLD $ 220.32 $ 0.75 (0.34 %)
$ 8.1299
$ 8.61
$ 0.00 x 0
$ 8.03 x 100
$ 8.61 - $ 8.61
$ 6.58 - $ 17.05
2,660
na
-6
$ 2.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 valneva-announces-the-initiation-of-phase-1-trial-of-second-generation-zika-vaccine-candidate

The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to ...

 guggenheim-maintains-buy-on-valneva-lowers-price-target-to-17

Guggenheim analyst Evan Wang maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $18 to $17.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-raised-2024-product-sales-guidance-to-160m-180m-prior-150m-180m-sees-total-revenues-of-170m-190m

Updated FY 2024 guidance Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an ...

 national-cinemedia-reports-upbeat-results-joins-nordstrom-core--main-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

 valneva-extends-interest-only-payment-term-for-its-loan-facility-with-deerfield-and-orbimed

Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024. Maturity of this first tr...

 smith--wesson-brands-reports-upbeat-earnings-joins-americas-car-mart-hci-group-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 us-centers-for-disease-control-and-preventions-advisory-committee--recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ® Recommendation fo...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valnevas-2024-guidance-expects-product-sales-of-150m-180m-reflecting-continued-revenue-growth-for-proprietary-products-and-ixchiqs-launch-year-sales

First full year 2024 guidance Product sales expected between €150 million and €180 million, reflecting continued revenue gro...

 valnevas-2023-revenues-1537m-down-from-3613m-yoy-product-sales-grew-26-yoy-to-1446m

Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sale...

 chikungunya-vaccine-maker-valneva-secures-non-dilutive-funding-to-developexpand-its-clinical-pipeline

Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikung...

 mcdonalds-caterpillar-and-3-stocks-to-watch-heading-into-monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as foll...

 valneva-sells-priority-review-voucher-from-the-us-food-and-drug-administration-for-103m

The Company was awarded a tropical disease PRV in November 20231 following U.S. FDA approval of IXCHIQ®, Valneva's single-d...

Core News & Articles

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA159,437* participants en...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION